GlassScriptPhysician profile
Lauren E Walters
NPI 1780007971
$7,052.95
in general payments reported to CMS, 2019-2025
28 companies · $202 in 2025
The $202 reported for 2025 was less than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,253 · 2022: $2,037 · 2023: $1,627 · 2024: $934 · 2025: $202.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,682 · Education: $80.86.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,681.88 |
| Education | $80.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,468.10 | 2021-2025 | Fasenra, Tezspire, Airsupra |
| Glaxosmithkline, LLC. | $969.20 | 2021-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Takeda Pharmaceuticals U.S.A., INC. | $728.41 | 2021-2024 | Hyqvia, Cuvitru, Takhzyro |
| Genzyme Corporation | $607.73 | 2021-2024 | |
| Optinose US, INC. | $438.83 | 2021-2024 | |
| Csl Behring | $336.89 | 2021-2025 | Hizentra, Haegarda |
| Pfizer INC. | $262.44 | 2021-2023 | |
| Regeneron Healthcare Solutions, INC. | $255.21 | 2021-2024 | Dupixent |
| Amgen INC. | $236.30 | 2021-2025 | Tezspire |
| Alk-Abello, INC | $211.87 | 2021-2023 | Odactra, Grastek, Ragwitek |
| Novartis Pharmaceuticals Corporation | $208.73 | 2021-2023 | |
| Pharming Healthcare, INC. | $205.85 | 2021-2023 | Ruconest |
| Teva Pharmaceuticals USA, INC. | $199.48 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $172.50 | 2021-2022 | |
| Kaleo, INC. | $147.07 | 2021-2024 | Auvi-Q |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $142.79 | 2022-2023 | Adbry |
| Biocryst US Sales Co., LLC | $106.28 | 2022-2023 | Orladeyo |
| Abbvie INC. | $90.14 | 2021-2022 | |
| Covis Pharma Gmbh | $45.53 | 2021-2022 | |
| Bio Products Laboratory USA, INC. | $45.07 | 2021 | |
| Genentech USA, INC. | $35.94 | 2023-2024 | Xolair |
| Aimmune Therapeutics, INC. | $25.17 | 2022 | |
| Octapharma USA, INC. | $23.49 | 2023 | Panzyga |
| Blueprint Medicines Corporation | $23.29 | 2023 | Ayvakit |
| Organon LLC | $19.08 | 2025 | Vtama |
| Mylan Specialty L.P. | $16.74 | 2023 | Yupelri |
| Phadia US INC. | $16.12 | 2021 | |
| Hikma Pharmaceuticals USA | $14.70 | 2023 | Ryaltris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lauren Walters listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.